Arterial blood gas analysis must for detecting severe resting hypoxemia in COPD in addition to pulse oximetry

Written By :  Niveditha Subramani
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-12-18 04:00 GMT   |   Update On 2023-12-18 09:23 GMT

Chronic obstructive pulmonary disease (COPD) is globally the third leading cause of death, causing 3.23 million deaths in 2019. Most feasible way to measure oxygen saturation is by pulse oximetry (SpO2). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend evaluation with arterial blood gas (ABG) analysis if SpO2 is ⩽92%. This recommendation has not...

Login or Register to read the full article

Chronic obstructive pulmonary disease (COPD) is globally the third leading cause of death, causing 3.23 million deaths in 2019.

Most feasible way to measure oxygen saturation is by pulse oximetry (SpO2). The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend evaluation with arterial blood gas (ABG) analysis if SpO2 is ⩽92%.

This recommendation has not been evaluated in stable outpatients with COPD undergoing testing for Long-Term Oxygen Therapy (LTOT) to evaluate whether the performance of SpO2 compared with ABG analysis of PaO2 and arterial oxygen saturation (SaO2) to detect severe resting hypoxemia in patients with COPD a team of researchers conducted a study.

The study published in Annals of American Thoracic Society, reports that SpO2 alone may have a high false-negative (FN) rate for detecting severe resting hypoxemia in COPD patients being assessed for long-term oxygen therapy (LTOT). The GOLD recommends reflex measurement of PaO2 through ABG analysis. This is crucial, particularly for active smokers, and it is advisable to use a cutoff higher than SpO2 ⩽92%.

Researchers conducted a Retrospective analysis of paired SpO2 and ABG values from stable outpatients with COPD who underwent LTOT assessment in a single center. They calculated false negatives (FNs) as an SpO2 >88% or >89% in the presence of pulmonary hypertension with a PaO2 ⩽55 mm Hg or ⩽59 mm Hg in the presence of pulmonary hypertension. Test performance was assessed using receiver operating characteristic (ROC) analysis, intraclass correlation coefficient (ICC), test bias, precision, and accuracy root-mean-square (Arms). An adjusted multivariate analysis was used to evaluate factors affecting SpO2 bias.

The key findings of the study are

• A total of 518 patients were included, the prevalence of severe resting hypoxemia was 74 (14.3%), with 52 missed by SpO2 (FN, 10%), including 13 (2.5%) with an SpO2 > 92% (occult hypoxemia).

• FNs and occult hypoxemia in Black patients were 9% and 1.5%, respectively, and were 13% and 5%, respectively, among active smokers.

• The correlation between SpO2 and SaO2 was acceptable (ICC = 0.78; 95% confidence interval, 0.74–0.81); and the bias of SpO2 was 0.45%, with a precision of 2.6 (−4.65 to +5.55%) and Arms of 2.59.

• These measurements were similar in Black patients, but in active smokers, correlation was lower and bias showed greater overestimation of SpO2.

• ROC analysis suggests that the optimal SpO2 cutoff to warrant LTOT evaluation by ABG analysis is ⩽94%.

In conclusion, “SpO2 as the only measure of oxygenation carries a high FN rate in detecting severe resting hypoxemia in patients with COPD undergoing evaluation for LTOT. Reflex measurement of PaO2 by ABG analysis should be used as recommended by GOLD, ideally at a cutoff higher than an SpO2 ⩽92%, especially in active smokers.”

Reference: Brian Garnet , Rodrigo Diaz-Lankenau , Elie Jean et al ; Accuracy of Pulse Oximetry for Long-Term Oxygen Therapy Assessment in Chronic Obstructive Pulmonary Disease; Ann. Of Am. Thor. Soc. DOI:https://doi.org/10.1513/AnnalsATS.202209-837OC

Tags:    
Article Source : Annals of American Thoracic Society

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News